Immunotherapy Impact Extends to Mesothelioma – OncLive
OncLive |
Immunotherapy Impact Extends to Mesothelioma
OncLive Although the only FDA-approved regimen for the treatment of patients with pleural malignant mesothelioma is the chemotherapy combination of pemetrexed and cisplatin, clinical trials of combination immunotherapy are showing impressive overall survival … |
